{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RAS+Mutation&page=2", "query": { "condition": "RAS Mutation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RAS+Mutation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T02:10:42.682Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07224815", "title": "cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "CRC (Colorectal Cancer)" ], "interventions": [ { "name": "cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase)", "type": "DIAGNOSTIC_TEST" }, { "name": "EpiCORE Assay (Targeted Sequencing / qPCR Validation)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-06-21", "completion_date": "2026-06-18", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224815" }, { "nct_id": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Histiocytic Neoplasm", "Histiocytosis", "BRAF Gene Mutation", "BRAF V600E", "BRAF V600 Mutation", "BRAF Mutation-Related Tumors", "BRAF", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "Recurrent Lung Cancer", "Recurrent Lung Non-Small Cell Carcinoma", "NSCLC", "Solid Tumor", "Solid Carcinoma", "KRAS G12D", "KRAS G12V", "KRAS Mutation-Related Tumors", "NRAS Gene Mutation", "Thyroid Cancer", "Thyroid Carcinoma", "Colorectal Cancer", "Colorectal Carcinoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Brain Metastases", "Recurrent NSCLC", "KRAS G13C", "Acquired Resistance to KRAS G12C Inhibitor", "KRAS G12A", "KRAS G12F", "KRAS G12R", "KRAS G13D" ], "interventions": [ { "name": "S241656", "type": "DRUG" }, { "name": "FOLFOX6/FOLFOX7", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 554, "start_date": "2023-04-18", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786924" }, { "nct_id": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "PF-07284892", "type": "DRUG" }, { "name": "lorlatinib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2021-03-17", "completion_date": "2024-06-19", "has_results": false, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Encinitas, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04800822" }, { "nct_id": "NCT01298570", "title": "Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "Regorafenib (BAY 73-4506)", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2011-04-07", "completion_date": "2020-10-02", "has_results": true, "last_update_posted_date": "2021-01-06", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 23, "location_summary": "Denver, Colorado • Miami, Florida • Tampa, Florida + 19 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01298570" }, { "nct_id": "NCT03271047", "title": "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MSS", "RAS-mutant Colorectal Cancer" ], "interventions": [ { "name": "binimetinib", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2017-10-18", "completion_date": "2021-02-25", "has_results": true, "last_update_posted_date": "2022-01-04", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 33, "location_summary": "Los Angeles, California • Santa Monica, California • Newark, Delaware + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271047" }, { "nct_id": "NCT01907815", "title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Adult Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Akt Inhibitor GSK2141795", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-10", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2018-04-06", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 3, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907815" }, { "nct_id": "NCT06208124", "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor (Phase 1)", "Pancreas Adenocarcinoma", "Non-small Cell Lung Cancer", "Malignant Melanoma (Cutaneous)" ], "interventions": [ { "name": "IMM-6-415", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immuneering Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-27", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208124" }, { "nct_id": "NCT06162221", "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer, NSCLC", "KRAS, NRAS, HRAS-mutated NSCLC", "KRAS G12C-mutated Solid Tumors, Lung Cancer", "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer", "RAS G12D-mutated NSCLC" ], "interventions": [ { "name": "RMC-6291", "type": "DRUG" }, { "name": "RMC-6236", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "RMC-9805", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 616, "start_date": "2024-01-18", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 26, "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 21 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06162221" }, { "nct_id": "NCT05907304", "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "Naporafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Erasca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "12 Years to 99 Years" }, "enrollment_count": 86, "start_date": "2023-08-17", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 14, "location_summary": "San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05907304" }, { "nct_id": "NCT02418000", "title": "A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML", "MDS", "CMML" ], "interventions": [ { "name": "E6201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spirita Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2015-04-10", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-05-22T02:10:42.682Z", "location_count": 4, "location_summary": "Denver, Colorado • Tampa, Florida • Houston, Texas + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02418000" } ] }